Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK

View through CrossRef
Introduction: BCR-ABL1-negative myeloproliferative disorders are a sub-group of myeloproliferative neoplasms (MPNs) that consist of polycythemia Vera (PV), Essential thrombocythemia (ET) and Primary Myelofibrosis (PMF). Over the past decade, the morphological and clinical division of myeloproliferative neoplasms (MPN) has changed to a classification that describes the molecular heterogeneity and is unique to this subgroup of haematological malignancies. This includes alterations in Janus kinase 2 (JAK2), and MPL genes. Objective: To determine the frequency of JAK2 (p.V617F) and MPL (p.W515L) mutation in primary myelofibrosis in KPK province of Pakistan. Methodology: Fifty patients with PMF were enrolled in the study. JAK2 mutation status was determined using allele specific primers and MPL mutation was detected by direct Sanger sequencing technique. The data was analyzed using BioEdit by aligning the sequence data with reference genome hg19 assembly. Results: Among 50 patients, 41 patients were diagnosed with PMF, while 9 patients had secondary myelofibrosis i.e. Post PV-MF and Post ET-MF. Out of the 41 PMF patient 2 patients had MPL gene variation, while one of the Post ET –MF had a MPL gene variation.  Forty eight (96%) were positive for JAK2 mutation. Five patients who had MPL mutation also showed JAK 2 mutation. Two of the MPL positive patients were also positive for JAK2 mutation. Conclusion: We reported rate of recurrence of JAK2 mutation in 96% of the cases and MPL exon 10 mutations in 6% of the cases. Keywords: JAK2, MPL, Myeloproliferative neoplasms.
Title: Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
Description:
Introduction: BCR-ABL1-negative myeloproliferative disorders are a sub-group of myeloproliferative neoplasms (MPNs) that consist of polycythemia Vera (PV), Essential thrombocythemia (ET) and Primary Myelofibrosis (PMF).
Over the past decade, the morphological and clinical division of myeloproliferative neoplasms (MPN) has changed to a classification that describes the molecular heterogeneity and is unique to this subgroup of haematological malignancies.
This includes alterations in Janus kinase 2 (JAK2), and MPL genes.
Objective: To determine the frequency of JAK2 (p.
V617F) and MPL (p.
W515L) mutation in primary myelofibrosis in KPK province of Pakistan.
Methodology: Fifty patients with PMF were enrolled in the study.
JAK2 mutation status was determined using allele specific primers and MPL mutation was detected by direct Sanger sequencing technique.
The data was analyzed using BioEdit by aligning the sequence data with reference genome hg19 assembly.
Results: Among 50 patients, 41 patients were diagnosed with PMF, while 9 patients had secondary myelofibrosis i.
e.
Post PV-MF and Post ET-MF.
Out of the 41 PMF patient 2 patients had MPL gene variation, while one of the Post ET –MF had a MPL gene variation.
  Forty eight (96%) were positive for JAK2 mutation.
Five patients who had MPL mutation also showed JAK 2 mutation.
Two of the MPL positive patients were also positive for JAK2 mutation.
Conclusion: We reported rate of recurrence of JAK2 mutation in 96% of the cases and MPL exon 10 mutations in 6% of the cases.
Keywords: JAK2, MPL, Myeloproliferative neoplasms.

Related Results

TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
Chronic myeloid leukemia (CML) is a hematopoietic malignancy caused by the BCR-ABL fusion gene. Although tyrosine kinase inhibitors (TKIs) targeting the oncoprotein BCR-ABL have dr...
PS1446 THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F‐POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
PS1446 THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F‐POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
Background:Constitutive activation of the Jak/Stat signalling pathway is a hallmark of Myeloproliferative Neoplasms (MPN), with 60–90% of patients carrying the activating JAK2 muta...
PARP Inhibition Sensitize BCR-ABL1 Positive Cel
PARP Inhibition Sensitize BCR-ABL1 Positive Cel
Introduction: BCR-ABL1 play a key role in the development of chronic myelogenous leukemia and a part of Ph1 positive acute lymphoblastic leukemia (ALL). BCR-ABL1 fun...
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can present with a variety of clinical manifestations, ranging from mild skin involvement to multisystemic ...
Determination of the JAK2 V617F mutation in thrombosis patients
Determination of the JAK2 V617F mutation in thrombosis patients
Background: Janus kinase 2 (JAK2) gene mutation causes uncontrolled myeloproliferation independent of cytokines and abnormal formation of the endogenous erythroid colony. JAK2 muta...

Back to Top